These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 24433041)

  • 1. Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
    Luttrell LM
    Mol Endocrinol; 2014 Mar; 28(3):281-94. PubMed ID: 24433041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating in vitro ligand bias into in vivo efficacy.
    Luttrell LM; Maudsley S; Gesty-Palmer D
    Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
    Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
    Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining efficacy: exploiting functional selectivity for drug discovery.
    Gesty-Palmer D; Luttrell LM
    Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
    Bohinc BN; Gesty-Palmer D
    Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrestin pathways as drug targets.
    Luttrell LM
    Prog Mol Biol Transl Sci; 2013; 118():469-97. PubMed ID: 23764065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.
    Reiter E; Ahn S; Shukla AK; Lefkowitz RJ
    Annu Rev Pharmacol Toxicol; 2012; 52():179-97. PubMed ID: 21942629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased agonism: An emerging paradigm in GPCR drug discovery.
    Rankovic Z; Brust TF; Bohn LM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):241-250. PubMed ID: 26707396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
    Stott LA; Hall DA; Holliday ND
    Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.
    Digby GJ; Conn PJ; Lindsley CW
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):587-94. PubMed ID: 20812150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.
    DeWire SM; Violin JD
    Circ Res; 2011 Jul; 109(2):205-16. PubMed ID: 21737816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating structural and molecular mechanisms of β-arrestin-biased agonism at GPCRs via MS-based proteomics.
    Xiao K; Sun J
    Cell Signal; 2018 Jan; 41():56-64. PubMed ID: 28939107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric coupling and biased agonism in G protein-coupled receptors.
    Bock A; Bermudez M
    FEBS J; 2021 Apr; 288(8):2513-2528. PubMed ID: 33621418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery.
    Slosky LM; Caron MG; Barak LS
    Trends Pharmacol Sci; 2021 Apr; 42(4):283-299. PubMed ID: 33581873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A kinetic view of GPCR allostery and biased agonism.
    Lane JR; May LT; Parton RG; Sexton PM; Christopoulos A
    Nat Chem Biol; 2017 Aug; 13(9):929-937. PubMed ID: 28820879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biased ligands at G-protein-coupled receptors: promise and progress.
    Violin JD; Crombie AL; Soergel DG; Lark MW
    Trends Pharmacol Sci; 2014 Jul; 35(7):308-16. PubMed ID: 24878326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergent biological properties of arrestin pathway-selective biased agonism.
    Appleton KM; Luttrell LM
    J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors.
    Lymperopoulos A
    Curr Pharm Des; 2012; 18(2):192-8. PubMed ID: 22229558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.